Updating results

74 results for Bevacizumab Sort: Relevance | Date

Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer

Technology appraisal guidance Published January 2007 Last updated January 2012

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published August 2012

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published February 2011

Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

Evidence-based recommendations on bevacizumab (Avastin) in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

Technology appraisal guidance Published May 2013

Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)

NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published June 2008

Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

Evidence-based recommendations on bevacizumab (Avastin) with oxaliplatin and fluorouracil plus folinic acid or capecitabine for metastatic colorectal cancer

Technology appraisal guidance Published December 2010

Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)

NICE is unable to make recommendations about the use of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or…

Technology appraisal guidance Published August 2015

Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) (TA436)

NICE was unable to make a recommendation about the use in the NHS of bevacizumab for epidermal growth factor receptor mutation-positive non-small-cell lung

Technology appraisal guidance Published March 2017

ESUOM21: Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment

Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

Evidence summary Published October 2013

Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)

Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema secondary to retinal vein occlusion

Technology appraisal guidance Published July 2011

Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion

Technology appraisal guidance Published May 2013

Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia

Technology appraisal guidance Published November 2013

Ovarian cancer

Everything NICE has said on recognising and managing ovarian cancer in an interactive flowchart

NICE Pathway Published February 2012 Last updated July 2018

Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults

Technology appraisal guidance Published August 2016

Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion

Technology appraisal guidance Published February 2014

Colorectal cancer

Everything NICE has said on diagnosing and managing colorectal cancer in an interactive flowchart

NICE Pathway Published November 2011 Last updated July 2018

Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

Evidence-based recommendations on aflibercept (Eylea) solution for injection for treating wet age-related macular degeneration

Technology appraisal guidance Published July 2013

Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion

Technology appraisal guidance Published September 2016

Age-related macular degeneration (NG82)

Evidence-based recommendations on diagnosing and managing age-related macular degeneration (AMD) in adults

NICE guideline Published January 2018

Renal cancer

Everything NICE has said on renal (kidney) cancer in an interactive flowchart

NICE Pathway Published December 2013 Last updated January 2019

Advanced breast cancer

Everything NICE has said on diagnosing and treating advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated March 2018

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)

Evidence-based recommendations on sunitinib (Sutent) for the first-line treatment of advanced and/or metastatic renal cell carcinoma

Technology appraisal guidance Published March 2009

Colorectal cancer: diagnosis and management (CG131)

Evidence-based recommendations on diagnosing and managing colorectal cancer (cancer of the colon and the rectum) in adults

Clinical guideline Published November 2011 Last updated December 2014

Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 04 March 2019.

Technology appraisal guidance In consultation

Proposed technology appraisals

page. No further topics will be added. Jump to: Exploratory work of bevacizumab in eye conditions Inhaled alpha-1 antitrypsin for...

Published May 2018

Static list

NICE technology appraisal guidance static list

Published January 2018

Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

Evidence-based recommendations on the My5-FU assay for guiding dose adjustment for fluorouracil chemotherapy

Diagnostics guidance Published December 2014

Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its effects on health-related quality of life.

TA263/1 Question Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its effects on...

Research recommendation Published June 2015

Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults

Technology appraisal guidance Published October 2018

Block scoping reports

NICE block scoping reports

Published January 2019

Past appeals and decisions

aflibercept 23 January 2014 TA118 Colorectal cancer (metastatic) - bevacizumab & cetuximab 27 November 2006 TA102 Conduct disorder in...

Published January 2019

Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.

differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior...

Research recommendation Published June 2015

NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be...

Research recommendation Published June 2015

NICE concluded that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema secondary to retinal vein occlusion should be conducted.

directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema secondary to retinal...

Research recommendation Published June 2015

Glioblastoma - bevacizumab [ID80]

In development [GID-TAG413] Expected publication date: TBC

Technology appraisal guidance In development

Bevacizumab for untreated malignant pleural mesothelioma (ID1183)

In development [GID-TA10197] Expected publication date: TBC

Technology appraisal guidance In development

Tivozanib for treating advanced renal cell carcinoma (TA512)

Evidence-based recommendations on tivozanib (Fotivda) for previously untreated advanced renal cell carcinoma (RCC/kidney cancer) in adults

Technology appraisal guidance Published March 2018

Lung cancer

Everything NICE has said on diagnosing and treating lung cancer in an interactive flowchart

NICE Pathway Published March 2012 Last updated January 2019

Brain tumours (primary) and brain metastases in adults (NG99)

Evidence-based recommendations on diagnosing, monitoring and managing brain tumours (primary) and brain metastases in adults

NICE guideline Published July 2018

Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)

Evidence-based recommendations on capecitabine (Xeloda) and oxaliplatin (Eloxatin) for adjuvant treatment of stage III (Dukes' C) colon (bowel) cancer

Technology appraisal guidance Published April 2006

Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]

In development [GID-TAG432] Expected publication date: TBC

Technology appraisal guidance In development

Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]

In development [GID-TA10149] Expected publication date: TBC

Technology appraisal guidance In development